Compare Amphastar Pharmaceuticals Inc (AMPH) vs Equinor ASA (EQNR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Equinor ASA — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Equinor ASA trades at $34.59 (market cap $78.18B). The key difference: Equinor ASA is far larger — about 94.6× Amphastar Pharmaceuticals Inc's market cap, and Equinor ASA pays a 4.48% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | EQNR | |
|---|---|---|
Market Cap | $826.08M | $78.18B |
Sector | Health | Energy |
52-Week High | $30.81 | $42.40 |
52-Week Low | $16.87 | $22.41 |
Enterprise Value | $1.22B | $89.94B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Equinor (EQNR) trades at $33.92, down 0.26% today, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating estimates in Q4 2025 and Q1 2026 but missing in Q3 2025. Recent news highlights strategic investments in Norwegian Continental Shelf projects and a share buy-back program. Valuation ratios appear attractive with a P/E of 15.35 and EV/EBITDA of 2.27, though net income margin has declined to 5.3% in 2025 from 19.29% in 2022.
EQNR presents a value opportunity with low valuation multiples and ongoing shareholder returns via dividends and buybacks. However, declining profitability and negative net cash flow trends pose risks. Analyst sentiment is mixed with 30% buy ratings but 57% hold, suggesting cautious optimism. Key catalysts include production growth from recent investments, while oil price volatility and execution risks remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
